09:48 AM EST - Knight Therapeutics Inc. : Has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis within the Territory. Knight Therapeutics Inc.
shares T.GUD are trading up $0.37 at $5.61.
